

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
18 December 2003 (18.12.2003)


PCT

(10) International Publication Number  
WO 03/104771 A1

- (51) International Patent Classification<sup>7</sup>: G01N 15/12, 33/80
- (74) Agent: ALBIHNS A/S; H.C. Andersens Boulevard 49, DK-1553 Copenhagen V (DK).
- (21) International Application Number: PCT/DK03/00383
- (22) International Filing Date: 11 June 2003 (11.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/387,407 11 June 2002 (11.06.2002) US  
PA 2003 00159 5 February 2003 (05.02.2003) DK
- (71) Applicant (for all designated States except US): CHEMPAQ A/S [DK/DK]; Symbion Science Park, Fruebjergvej 3, Box 38, DK-2100 Copenhagen Ø (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LARSEN, Ulrik, Darling [DK/DK]; Solbakken 115, DK-2840 Holte (DK). HANSEN, Stine, Hallberg [DK/DK]; Nygårdsterrasse 265 F, DK-3520 Farum (DK). EKBERG, Bjørn [SE/SE]; Nordmannagatan 16, SE-21774 Malmö (SE).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report

[Continued on next page]

(54) Title: LYSING REAGENT, CARTRIDGE AND AUTOMATIC ELECTRONIC CELL COUNTER FOR SIMULTANEOUS ENUMERATION OF DIFFERENT TYPES OF WHITE BLOOD CELLS



(57) Abstract: The present invention relates to a lysing reagent for use in the simultaneous automatic electronic enumeration and volumetric discrimination of different types of blood cells, such as leukocytes, thrombocytes, etc, in blood. Further, the present invention relates to a Coulter ( impedance) counting apparatus containing the lysing reagent, for example a Coulter counting apparatus with a disposable cartridge for characterizing cells suspended in a liquid, especially a self-contained disposable cartridge for single-use analysis, such as for single-use analysis of a small quantity of whole blood.

WO 03/104771 A1

BEST AVAILABLE COPY

WO 03/104771 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

LYSING REAGENT, CARTRIDGE AND AUTOMATIC ELECTRONIC CELL COUNTER FOR  
SIMULTANEOUS ENUMERATION OF DIFFERENT TYPES OF WHITE BLOOD CELLS

A lysing reagent for the simultaneous enumeration of different types of white blood cells

The present invention relates to a lysing reagent for use in the simultaneous automatic electronic enumeration and volumetric discrimination of different types of blood cells, such as leukocytes, thrombocytes, etc, in blood. Further, the present invention relates to a Coulter (impedance) counting apparatus containing the lysing reagent, for example a Coulter counting apparatus with a disposable cartridge for characterizing cells suspended in a liquid, especially a self-contained disposable cartridge for single-use analysis, such as for single-use analysis of a small quantity of whole blood.

The three types of blood cells erythrocytes, leukocytes and thrombocytes differ in a) size, b) occurrence and c) structure.

- a) Their size, expressed as diameter, ranges from 2  $\mu\text{m}$  for the smallest thrombocytes to 20  $\mu\text{m}$  for the largest leukocytes.
  - b) Their occurrence normally ranges from typically  $4.10^9/\text{L}$  blood for leukocytes to typically  $4.10^{12}/\text{L}$  blood for erythrocytes.
    - c 1) The thrombocytes contain organelles such as microfilaments, granules (including so called dense-bodies) and mitochondria, surrounded by a cell membrane. This membrane is in its turn surrounded by an so-called surface coat.
    - c 2) The most distinct leukocyte organelle is the microscopically visible granule, which has different structure in the different leukocyte sub-populations.
    - c 3) The erythrocytes cell membrane does, however, not surround any organelles as mentioned above. Finally, the three types of blood cells have different shape. (Clinical Haematology, Ed. M. M. Wintrobe, 1981, 8th Ed, Lia & Febiger, Philadelphia, USA)
- Information on the content of leukocytes, their subpopulations and thrombocytes is an important tool for the physician in order to diagnose different diseases and monitor treatment. Furthermore, the concentration of haemoglobin, directly related to the number of erythrocytes, in the blood sample is also of great importance.

Thus, much effort has over the years been devoted to the development of automated blood cell counting systems. For the sake of completeness, manual counting using microscope techniques of blood cells using smears of blood samples should also be mentioned here. The latter techniques are, however, time-consuming and require

relatively high level of training by the performer. Automated blood cell counting systems can be divided into two major groups: those relying on the impedance cell sizing principle (equal to the Coulter principle) and those relying on the flow cytometry principle. Examples of such automated systems are Coulter AcT Diff based on  
5 impedance cell sizing and Bayer ADVIA 120 based on flow cytometry. Both principles can be combined with spectrophotometric techniques for additional analysis of soluble components in the blood, such as haemoglobin.

The automated blood cell counting systems analyse the number of erythrocytes and thrombocytes simultaneously using a special procedure involving dilution of the blood  
10 sample with cell-preserving reagent. The number of leukocytes are on the other hand separately analysed by exposing the blood sample to a lysing reagent containing compounds capable of lysing the erythrocytes since they interfere with the enumeration of the leukocytes. The interference, not using erythrocyte-lysing compounds, is due to the overlap in cell size and it is thus not possible to count the  
15 leukocytes in the presence of the erythrocytes by size discrimination alone.

The lysing reagent does also affect the leukocytes but only to such an extent that these can still be enumerated. As a consequence of lysing the erythrocytes, the haemoglobin is released and can thus be properly analysed using spectrophotometric techniques. A great number of (erythrocyte) lysing reagents mixtures have been  
20 developed. In these mixtures specific compounds, surfactants, are responsible for the lysing action. Examples of such compounds are quaternary ammonium salts as described in US 4 485 175, US 4 346 018, US 4 745 071, US 4 528 274, US 5 763 280, US 5 834 315 and saponins as described in US 4 751 179, US 5 731 206, US 5 840 515, US 5 348 859, EP 0549 414 B1. Different lysing reagent in the automatic  
25 blood cell counting systems as described above have different effect on the system to enumerate the three leukocyte subpopulations: lymphocytes, monocytes and granulocytes. In order to also be able to enumerate the three granulocytes subpopulations: eosinophils, basophils and neutrophils the lysing reagent also contains specific compounds rendering these three subpopulations different properties. As an  
30 alternative these three granulocytes subpopulations can be enumerated using complementary radio frequency analysis contained in the automated blood cell counting systems based on the impedance cell sizing principle.

In EP 0549 414 B1, a process is disclosed wherein a combined enumeration of erythrocytes and thrombocytes in a blood sample is performed followed by addition of

an erythrocyte lysing agent whereafter the remaining thrombocytes are enumerated again. Finally, the number of the erythrocytes and the thrombocytes, respectively, is calculated.

According to the present invention, an improved method and apparatus is provided  
5 for enumeration of different types of blood cells, such as different types of white blood cells, such as leukocytes, thrombocytes, etc, in blood. The method and apparatus involve counting and distinguishing the different types in one counting operation, e.g. in a flowcytometer, in a Coulter counter, etc. A lysing reagent is added to a blood sample for lysing of the erythrocytes. The composition of the lysing reagent is  
10 accurately controlled so that the required lysing is performed without deteriorating the cell types that it is desired to enumerate. For example, in a Coulter counter, the diameter of the orifice is optimised for counting of cell sizes corresponding to the cell sizes of the different types of cells it is desired to enumerate after lysing by the lysing reagent.

15 For example, the lysing reagent according to the present invention may be contained in a cartridge utilised in an apparatus for enumeration of cells in a blood sample, comprising a housing with a first mixing chamber and a first collection chamber separated by a wall containing an orifice for passage of the cells between the first mixing chamber and the first collection chamber. Cell characterization means are  
20 provided for characterizing cells passing through the orifice. The apparatus comprises a docking station for removably receiving the cartridge, the docking station comprising connectors for operational connection with the cell characterization means when the cartridge is received in the docking station.

With the electrical impedance technique of the Coulter counter principle, it is possible  
25 to resolve the cell volume from the measurement. By maintaining a constant current across the orifice, the recorded voltage pulse from cells displacing the electrolyte in the orifice will have a height proportional to the volume of the cell. This is because cells can be considered non-conducting compared to the electrolyte, the electrical field (DC or RF) in the centre of the orifice is homogeneous, which is normally the  
30 case when the diameter  $D$  is smaller than the length  $l$  of the orifice ( $l/D > 1$ ), the cell  $d$  is to be considered small compared to the diameter of the orifice ( $d < 0.2 \cdot D$ ), only one cell passes through at a time and the cells are passed through the orifice along the length or depth of the orifice.

Preferably, the length of the orifice is from 1 to 1000  $\mu\text{m}$ , for example about 50  $\mu\text{m}$ . Desirably the length of the orifice is chosen such that only one cell will be present in the orifice at the time when detecting cells of from 0.1 to 100  $\mu\text{m}$  diameter. However, considerations to the homogeneity of the electrical field in the orifice may require a length of the orifice larger or equal to the diameter. The counts, of which some may be simultaneous counting of two cells, can be corrected mathematically by implementing a statistical estimation. The aspect ratio of the orifice, (length or depth divided by diameter) is preferably from 0.5:1 to 5:1, more preferably from 1:1 to 3:1.

Preferably, the largest cross-sectional dimension of the orifice is from 5 to 200  $\mu\text{m}$ , for example 10 to 50  $\mu\text{m}$ .

As a supplement a spectrophotometric measurement can be performed in order to quantify the content of e.g. haemoglobin.

The lysing reagent according to the present invention affects various types of blood cells. For example, the erythrocytes are completely eliminated, the leukocytes decrease in volume and the thrombocytes also decrease in volume. However, the composition of the lysing reagent is accurately controlled so that the decrease in volume of the thrombocytes is not significant for the ability of the thrombocytes to be counted in a Coulter counter. It has been verified that the identified parts of the remains of the thrombocytes were related to the original content of thrombocytes in the blood samples according to comparative methods. This is further described below.

The different behaviour of the different blood cells when exposed to the lysing reagent in question, can be explained taken the different structures of the three types of blood cells, as outlined above, into account and its consequence on the remains of these after exposure to the lysing reagent. The remains of the leukocytes are made up of the granula possibly surrounded by a collapsed cell membrane and/or a decreased amount of cytoplasm. The erythrocyte cell membrane disintegrates completely during the action of the lysing reagent. Since the erythrocytes do not contain any cell organelles, small cell membrane debris is the only remains of this blood cell type. This debris is difficult to separate from the background-noise of automatic blood cell counting systems based on the impedance cell sizing. The remains of the thrombocytes after exposure to the lysing reagent could be made up of cell organelles possibly surrounded by a collapsed cell membrane after complete disintegration of the outer surface coat.

In order to further separate the remains of the thrombocytes from the background-noise we found that use of an automatic blood cell system, based on impedance cell sizing principle, with a smaller orifice can be made. Using an orifice with a diameter of 50  $\mu\text{m}$ , 5 % of the thrombocytes present in the sample can thus be accounted for.

- 5 This part of the thrombocytes can be increased up to 49 % using an orifice with a diameter of 44  $\mu\text{m}$ . Finally, using an orifice with a diameter of 40  $\mu\text{m}$ , 63 % of the in the sample present thrombocytes can be accounted for.

The cartridge may comprise the following parts:

1. A liquid storage chamber
- 10 2. A blood-sampling device
3. A first mixing chamber
4. A flow through sensor arrangement
5. A first collection chamber
6. A volume metering arrangement comprised of a chamber and two connected  
15 flow channels
7. A hydraulic connection for moving the liquid through the cartridge

The concept of the disposable unit can be further combined with the following additional parts:

- A. Optical structures for optical liquid level measurement
- 20 B. Electrodes for liquid level measurement
- C. Anti-coagulation treatment of surfaces
- D. Reagents in the diluent for modification of e.g. blood cells
- E. Mixing flange or baffle for assisted mixing
- F. Multiple volume metering arrangements for altering volumes
- 25 G. A coating tape covering the sample inlet before use
- H. A waste chamber for waste/overflow
- I. A valve preventing liquid to exit through exhaust tube
- J. A piston or membrane instead of the vacuum tube
- K. A window for spectrophotometric measurements

The liquid storage chamber (part 1) holds the required amount of diluent used for the blood analysis. When the blood has been sampled into the cartridge, the diluent is flushed through the capillary to wash out the sampled blood and dilute it as required by the test. Dilutions of 100 to 100.000 times are considered to be normal ratings and  
5 dilutions of 500 to 10.000 times are preferred. The liquid storage chamber should preferably be constructed to facilitate total draining of the chamber. This would be accomplished by having a slanting of the bottom of the chamber.

The sampling unit (part 2) may comprise a capillary extending through a movable rod placed in a tight-fitting supporting body. The movable rod is used for entrapment of a  
10 precise amount of blood sample. When blood has filled the capillary by capillary forces, the rod is turned and/or displaced from its initial position in the supporting body, thus isolating the part of the capillary that extends through the rod.

After moving the rod in the supporting body into its second position the capillary forms a liquid path between the liquid storage chamber and the first mixing chamber  
15 (part 3). By applying a low pressure to the first mixing chamber the diluent and blood sample is forced into the first mixing chamber, where mixing will be performed by convection or subsequently by blowing bubbles into the mixing chamber.

The flow through sensor arrangement (part 4) is comprised of a small orifice in a membrane that establishes a liquid path from the first mixing chamber to the first  
20 collection chamber. On each side of the membrane (in the first mixing chamber and in the first collection chamber) an electrode is placed contacting the liquid.

The first collection chamber (part 5) forms a liquid priming function of the backside of the sensor system.

The volume metering system (part 6) is necessary for determination of the cell  
25 concentration. It comprises volume-metering chamber of a known volume with two relatively thin channels connecting the inlet at the bottom and the outlet at the top. Sensing of the liquid at the inlet and outlet can be applied by optical or electrical means.

The outlet of the volume metering system is connected through a channel (part 7) to  
30 a source of pressure for moving the liquid through the cartridge.

The additional parts to the concept are further described here:

Addition A: Optical detection by change of optical properties of a channel such as changed reflectance or transmittance due to replacement of air with liquid in the



channel. The surface over the inlet and outlet of the volume-metering cell should be structured to optimize the coupling of the light into the channel. The presence of liquid in a transparent polymer channel will result in a transmission of the signals as opposed to a reflection when no liquid is present, which can be registered by optical sensors.

Addition B: Two electrodes for liquid level measurement are connected through the body of the cartridge into the inlet and outlet of the volume-metering cell respectively. The electrodes will be short-circuited through the saline liquid to the electrode placed in the first collection chamber, which can be registered through an external electrical arrangement.

Addition C: The anti-coagulation treatment of surfaces in the sampling structure can be achieved by having selected compounds adhered or chemically bonded to these surfaces. Examples of such compounds are heparin and salts of EDTA.

Addition D: Reagent in the diluent for modification of e.g. blood cells. This reagent can consist of one or several compounds capable of hemolysing the erythrocytes. In addition other compounds may be added in order to: stabilize leukocytes and/or thrombocytes, adjust the pH-value and osmotic pressure, minimize bacterial growth, modify the haemoglobin present and minimize batch to batch variations. The following examples have been included to provide information on relevant subjects related to the performance of a self-contained test cartridge.

Examples of compounds capable of selectively hemolysing the red blood cells are: mixtures of quaternary ammonium salts as described in e.g. US 4,485,175; US 4,346,018; US 4,745,071; US 4,528,274; and US 5,834,315.

Examples of compounds capable of, during the hemolysis of the red blood cells, stabilizing the leukocytes are N-(1-acetamido)iminodiacetic acid, procaine hydrochloride as described in e.g. US 4,485,175 and 1,3-dimethylurea as described in e.g. US 4,745,071. In addition N-(1-acetamido)iminodiacetic acid is proposed to further assist the quaternary ammonium salts in minimizing debris stemming from hemolysed red blood cells as described in e.g. US 4,962,038 and adjust the pH-value (see below).

Examples of compounds added in order to adjust the pH-value and not least importantly the osmotic pressure of the diluent are: N-(1-acetamido)iminodiacetic

acid, sodium chloride, sodium sulphate as described in e.g. US 4,485,175 and US 4,962,038.

Examples of compounds capable of minimizing bacterial growth are: 1,3-dimethylolurea and chlorhexidine diacetate as described in e.g. US 4,962,038.

- 5 Examples of compounds added to convert the haemoglobin species to an end-product suitable for spectrophotometric analysis are: potassium cyanide as described in e.g. US 4,485,175; US 4,745,071; US 4,528,274 and tetrazole or triazole as described in WO 99/49319.

- 10 Examples of cells or compounds which may be added in order to introduce a tool for minimizing variation between different batches of the disposable device are: latex beads of known size and glass beads of known size.

- 15 Addition E: If assisted mixing is required the first mixing chamber might optionally include a mixing flea or a baffle. A magnetic flea may be used to force the convection through an externally moving magnetic field. A baffle may be used to mechanically stir the liquid when moved by an externally connecting mechanical device. This could be required if mixing with bubbles, such as bubbles blown into the sample through the sensor, is not adequate or possible.

Addition F: Multiple volume metering arrangements can be successively included if the test must deal with different concentrations of the different cells.

- 20 Addition G: A lid or coating tape may be used to cover the sample inlet before use. This ensures a clean sampling area at the origination of the test.

Addition H: A waste chamber may be applied at the outlet of the volume-metering cell for waste or overflow of liquid.

- 25 Addition I: At any connection ports, e.g. the connection port to the pressure source, a small valve can be integrated to prevent liquid to leak out of the cartridge.

Addition J: A piston or membrane can be integrated into the cartridge to include a source of pressure for moving the liquid. The piston or membrane could be moved by a mechanical force provided by the instrument.

- 30 Addition K: An optical window can be integrated into the cartridge in order to perform optical measurements such as spectrophotometric detection of the haemoglobin content in a blood sample.

The methods described can be combined to give the best solution for the final application. The disposable sensor is particularly usable where portable, cheap, simple or flexible equipment is needed, such as in small laboratories, in measurements in the field or as a "point of care" ("near-patient") diagnostic tool.

- 5 When using the Coulter principle the diluent for use in the apparatus according to the invention may contain inorganic salts rendering the liquid a high electrical conductivity. When sample is applied to the electrolyte, the electrolyte to sample volumes should preferably be higher than 10. Sample preparation should preferably result in between 1.000 to 10.000.000 cells per ml and more preferably between
- 10 10.000 and 100.000 cells per ml. A mixing of the sample after adding electrolyte is recommended. Cell diameters should preferably be within 1 to 60 percent of the orifice diameter and more preferably between 5 to 25 percent of the orifice diameter. Volume flow should preferably be from 10  $\mu$ l to 10 ml per minute and more preferably between 100  $\mu$ l and 1 ml per minute. For the measurement a constant electrical
- 15 current of approximately 1 to 5 mA should preferably be applied. The source of electrical current should preferably have a signal to noise ratio (S/N) better than 1.000. The response from the electrodes can be filtered electronically by a band-pass filter.

- According to yet another aspect of the invention a cartridge is provided comprising a
- 20 housing with a first mixing chamber and a first collection chamber separated by a wall containing a first orifice for the passage of the cells between the first mixing chamber and the first collection chamber, first cell characterization means for characterizing cells passing through the first orifice, a bore in the outer surface of the housing for entrance of the blood sample, communicating with a first sampling member
- 25 positioned in the housing for sampling the blood sample and having a first cavity for receiving and holding the blood sample, the member being movably positioned in relation to the housing in such a way that, in a first position, the first cavity is in communication with the bore for entrance of the blood sample into the first cavity, and, in a second position, the first cavity is in communication with the first mixing
- 30 chamber for discharge of the blood sample into the first mixing chamber.

The cartridge may further comprise a second mixing chamber and a second collection chamber separated by a second wall containing a second orifice for the passage of the cells between the second mixing chamber and the second collection

chamber, second cell characterization means for characterizing cells passing through the second orifice.

In one embodiment of the invention, the first cavity is in communication with the first mixing chamber, when the first sampling member is in its first position, for entrance of liquid from the first mixing chamber into the first cavity, and, in a third position of the first sampling member, the first cavity is in communication with the second mixing chamber for discharge of the liquid in the first cavity into the second mixing chamber.

In another embodiment of the invention, the cartridge further comprises a second sampling member positioned in the housing for sampling a small and precise volume of liquid from the first mixing chamber and having a second cavity for receiving and holding the sampled liquid, the member being movably positioned in relation to the housing in such a way that, in a first position, the second cavity is in communication with the first mixing chamber for entrance of liquid from the first mixing chamber into the first cavity, and, in a second position, the second cavity is in communication with the second mixing chamber for discharge of the sampled liquid in the second cavity into the second mixing chamber.

The cartridge may further comprise a reagent chamber positioned adjacent to the first mixing chamber for holding a reagent to be entered into the first mixing chamber.

Preferably, the cartridge further comprises a breakable seal separating the reagent chamber from the first mixing chamber.

With this embodiment, different chemical treatment of different parts of the blood sample may be performed.

Also with this embodiment, further dilution of the blood sample may be performed.

The invention will be further described and illustrated with reference to the accompanying drawings in which:

Fig. 1 illustrates cell volume reduction after treatment by the lysing reagent according to the present invention,

Fig. 2 is a histogram of cell sizes in a blood sample after treatment by the lysing reagent according to the present invention,

Fig. 3 shows a cross sectional side view through the components of a disposable unit 85, referred to as the cartridge,

Fig. 4 schematically illustrates the flow-through sensor concept

Fig. 5 illustrates an apparatus with a disposable cartridge, a docking station, and a reader,

Fig. 6 schematically illustrates the sampling procedure,

Fig. 7 schematically illustrates the cartridge and hydraulic connections,

5 Fig. 8 schematically illustrates a second embodiment of the cartridge,

Fig. 9 schematically illustrates a third embodiment of the cartridge, and

Fig. 10 shows in perspective an apparatus according to the invention.

The elimination of the erythrocytes and the decrease in volume of the leukocytes and thrombocytes after exposure to the lysing reagent is shown in Fig. 1a (before lysing) and 1b (after lysing). Further, as can be seen in Fig. 2, the leukocytes decrease so as  
10 and 1b (after lysing). Further, as can be seen in Fig. 2, the leukocytes decrease so as remains of them can be found in the particle size interval of 4 - 7  $\mu\text{m}$ . This should be compared to their original diameter of 8 to 20  $\mu\text{m}$ . Also, according to Fig. 2, the largest remains of the thrombocytes have a diameter of 2.5  $\mu\text{m}$ , which should be compared to their original range in diameter of 2 to 4  $\mu\text{m}$  (ref. M. L. Stevens,  
15 Fundamentals of Clinical Haematology, W.B. Saunders Company, 1997).

#### Example 1

Counting of thrombocytes, leukocytes, lymphocytes, monocytes and granulocytes.

Use of a reagent mixture containing quaternary ammonium salts.

#### Material

20 3 fresh venous blood samples in (K<sub>3</sub>)EDTA-collection tubes.

Coulter Particle Size and Particle Counter Z-2 equipped with a 50  $\mu\text{m}$  orifice.

Lysing reagent mixture: 0.450 g 1,2,4-Triazole, 0.178 g Dodecyltrimethylammonium chloride and 0.038 g Hexadecyltrimethylammonium bromide were dissolved in 90 ml Diluide III-Diff (J.T. Baker). To this solution 28.9 ml of de-ionised water was added.

25 The final solution was filtered (0.22  $\mu\text{m}$ ).

#### Methods

The samples were first analysed for comparative purposes using an ADVIA-120 (Bayer) system. Thereafter the blood samples were diluted 500 times by adding 20  $\mu\text{l}$  of them to 9.980 ml of lysing reagent mixture. Finally they were analysed on the  
30 Coulter Particle Size and Particle Counter within 2 minutes after dilution.

## Results

Fig. 2. shows a histogram for analysis of one of the blood samples. In this histogram the ranges used for correlation to the remains of the different blood cells are shown. Identical ranges were used in the analogous analysis of the remaining two blood samples.

5

<u>Blood sample</u>	<u>Analyte</u>	<u>Obtained result</u>	<u>Comparative result</u>	<u>Deviation#</u>
1	Thrombocytes	391 x 10e9	351 x 10e9	11
2	Thrombocytes	343 x 10e9	359 x 10e9	-4.4
3	Thrombocytes	340 x 10e9	300 x 10e9	13
1	Leukocytes	5.21 x 10e9	5.42 x 10e9	-4.0
2	Leukocytes	4.36 x 10e9	4.24 x 10e9	2.8
3	Leukocytes	5.33 x 10e9	5.35 x 10e9	-0.5
1	Lymphocytes	1.23 x 10e9	1.19 x 10e9	3.5
2	Lymphocytes	0.44 x 10e9	0.41 x 10e9	8.4
3	Lymphocytes	1.03 x 10e9	1.14 x 10e9	-9.8
1	Monocytes	0.27 x 10e9	0.30 x 10e9	-10
2	Monocytes	0.16 x 10e9	0.14 x 10e9	15.7
3	Monocytes	0.36 x 10e9	0.40 x 10e9	-10
1	Granulocytes	4.09 x 10e9	3.94 x 10e9	3.7
2	Granulocytes	3.92 x 10e9	3.69 x 10e9	6.2
3	Granulocytes	4.32 x 10e9	3.80 x 10e9	14

# )  $100 \times (\text{Obtained result} - \text{Comparative result}) / \text{Comparative result}$

Table 1.

### Example 2

Counting of thrombocytes, leukocytes, lymphocytes, monocytes and granulocytes.

10 Use of a reagent mixture containing saponin.

Material

Two fresh venous blood samples in (K<sub>3</sub>)EDTA-collection tubes.

Coulter Particle Size and Particle Counter Z-2 equipped with a 50 µm orifice.

Lysing reagent mixture: 2.063 g of Saponin (ACROS, prod. no. 41923100) was dissolved in 500 ml Diluide III-Diff (J.T. Baker). The final solution was filtered (0.22  $\mu\text{m}$ ).

#### Methods

- 5 The samples were first analysed for comparative purposes using an ADVIA-120 (Bayer) system. Thereafter the blood samples were diluted 500 times by adding 20  $\mu\text{l}$  of them to 9.980 ml of lysing reagent mixture. Finally they were analysed on the Coulter Particle Size and Particle Counter within 2 minutes after dilution.

#### Results

- 10 Identical ranges in the histogram (compare Fig. 2) were used in the analogous analysis of the two blood samples.

<u>Blood sample</u>	<u>Analyte</u>	<u>Obtained result</u>	<u>Comparative result</u>	<u>Deviation#</u>
1	Thrombocytes	189 x 10e9	190 x 10e9	-0.5
2	Thrombocytes	284 x 10e9	283 x 10e9	0.4
1	Leukocytes	5.41 x 10e9	5.12 x 10e9	5.6
2	Leukocytes	7.64 x 10e9	6.77 x 10e9	13
1	Lymphocytes	1.76 x 10e9	1.77 x 10e9	-0.8
2	Lymphocytes	1.64 x 10e9	1.64 x 10e9	0
1	Monocytes	0.25 x 10e9	0.24 x 10e9	4.2
2	Monocytes	0.22 x 10e9	0.26 x 10e9	-15
1	Granulocytes	3.28 x 10e9	3.11 x 10e9	5.3
2	Granulocytes	5.47 x 10e9	4.88 x 10e9	12

# )  $100 \times (\text{Obtained result} - \text{Comparative result}) / \text{Comparative result}$

Table 2.

- 15 Fig. 3 schematically illustrates a disposable cartridge with a housing 85 for blood analysis comprises a liquid storage chamber 1 containing a liquid diluent 11, a first sampling member 2 positioned in the housing 85 for sampling a blood sample 8 and having a cavity 10 for receiving and holding the blood sample 8, the member 2 being movably positioned in relation to the housing 85 in such a way that, in a first position, the cavity 10 is in communication with a bore 90 for entrance of the blood sample 8

into the cavity 10 by capillary forces, and, in a second position, the cavity 10 is in communication with the liquid storage chamber 1 and a mixing chamber 3 for discharge of the blood sample 8 diluted by the liquid diluent 11 into the mixing chamber 3. The mixing chamber 3 is separated by a wall containing an orifice 59  
5 from and a collection chamber 5 for the passage of the blood sample 8 between the mixing chamber 3 and the collection chamber 5. The wall containing the orifice 59 constitutes a part of a flow-through sensor 4.

A volume metering arrangement is connected to the collection chamber comprising a volume metering chamber 6 having the size of the volume to be measured during the  
10 measurement with two connecting channels 12, 13 of relatively diminutive internal volumes for registering liquid entry and exit by optical or electrical means, from the volume metering chamber a channel 7 leads out to a connection port 67 where a pressure can be applied.

Fig. 4 schematically illustrates, the flow-through sensor 4 has a dividing wall 91 with a  
15 relatively thin passage 59 for the passage of cells suspended in liquid. The passage serves as a sensing zone for detection and measurement of the individual cells. The passage in the sensor may be formed as a count orifice for counting and sizing cells by an impedance method known as Coulter counting. Cells can be aspirated through the orifice by pressure driven flow in either direction. When a saline or other  
20 electrolytic liquid solution is added to the chambers, the two chambers will be electrically isolated from each other except for the route for current flow provided by the passage through the orifice.

Fig. 5 illustrates an apparatus with a disposable cartridge, a docking station, and a reader. The chambers on each side of the flow through sensor have electrodes 34,  
25 35 extending from an external terminal 61, 62 through the base wall 63 of the disposable unit and into a configuration facing the inside of its respective chamber. The cartridge is placed in a docking station 66 in a portable apparatus in order to carry out the test. The docking station 66 has a cup shaped housing having a base 70 and a circumambient sidewall 71. In the base 70 there are respective spring  
30 loaded electrical connectors 64, 65 for contacting the terminals 61, 62 of the cartridge automatically when the cartridge is received as a push fit into the docking station. There is also a conduit 68 passing through the base wall 70 aligned with the conduit 67 of the cartridge. Conduit 67 at its opening into the upper face of the wall 70 has a seal 69, such as e.g. and O-ring for forming a gas tight connection with the lower face



of the base wall 63 of the cartridge. A vacuum pump 72 is connected by a line 73 to the lower end of the conduit 68. In a modification of the apparatus, the vacuum pump 72 can be reversed so as to apply positive gas pressure to the conduit 68.

5 Schematically indicated at 74 are the further conventional components of a Coulter counter including all the electronic circuitry and display equipment needed for the operation of the apparatus.

Fig. 6 schematically illustrates the blood sampling operation. The illustrated part of the cartridge 2 includes the liquid storage chamber 83 for storing a diluent for diluting the sample and the first mixing chamber 77 for mixing the sample 84 and the diluent.

10 This figure schematically illustrates a device for sampling a small and accurate volume of liquid in accordance with the present invention. The device 10 comprises a first member 86 with a first opening 87 for entrance of a blood sample into a bore 75 in the first member 86 and with a second opening 76 for outputting the blood sample from the bore 75. The bore 75 forms a capillary tunnel. The first opening 87 of the

15 first member 86 may be brought into contact with a liquid 8 (shown in Fig. 3), 84 to be sampled so that the liquid 84 may flow through the first opening 87 into the bore 75 and out of the second opening 76 by capillary attraction. The device 12 further comprises a sampling member 78 with a first cavity 82 for receiving and holding the blood sample 84 and having a third opening 88 communicating with the first cavity

20 82. The first cavity forms a capillary tunnel with essentially the same diameter as the bore 75. The sampling member 78 is a circular cylinder that is movably positioned in relation to the first member 86. During sampling of the liquid, the sampling member 78 is positioned in the illustrated first position in relation to the first member 86 wherein the second opening 76 is in communication with the third opening 88 so that

25 sampled liquid may flow through the second 76 and third opening 88 into the first cavity 82 by capillary attraction. The third opening 88 may be disconnected from the second opening 76 in a second position of the sampling member 78 in relation to the first member 86 so that the blood sample 84 contained in the first cavity 82 is disconnected from the bore 75.

30 The sampling member 78 is inserted into a third cavity 34 of the first member 86 for receiving and accommodating a part of the sampling member 78. The sampling member 78 may be displaced between the first and second position along a longitudinal axis of the sampling member 78 that is also substantially perpendicular to a longitudinal axis of the first cavity 82. The sampling member 78 may also be

35 rotatable about a longitudinal axis that is substantially perpendicular to a longitudinal

axis of the first cavity 82. In the first position, the first 75 and second 82 capillary tunnels extend along substantially the same longitudinal centre axis.

In the illustrated embodiment the first member 86 is symmetrical and has a fourth cavity 80 with openings 81, 79 opposite the bore 75, and the sampling member 78 has an opening 89 opposite the opening 88 so that, in the first position, a capillary tunnel extends through the first 86 and the second 78 member and communicates with the environment through openings 87, 79. Thus, air may escape from the capillary tunnel through opening 79. Further, in the first position, a part of the liquid entering the first cavity 82 will leave the cavity 82 through opening 89 thereby ensuring that the cavity 82 has been completely filled with liquid during liquid sampling eliminating the risk of sampling with a reduced sample volume leading to low accuracy sampling.

Fig. 6a illustrates the device 2 ready for receiving the liquid. In Fig. 6b, a sample has entered into the capillary tunnel 82, and in Fig. 6c the sampling member 78 has been rotated into the second position for isolation of an accurate volume of the sample 84, and finally Fig. 6d illustrates that the sample 84 has been washed out of the capillary tunnel 82 and into the first mixing chamber 77 by the diluent.

Example: The capillary tunnel forming the first cavity 82 may have a length of 8 mm and a diameter of 0.9 mm for containing a blood sample of 5.089  $\mu\text{L}$ .

Example: The capillary tunnel forming the first cavity 82 may have a length of 5 mm and a diameter of 0.5 mm for containing a blood sample of 0.982  $\mu\text{L}$ .

Example: The capillary tunnel forming the first cavity 82 may have a length of 3 mm and a diameter of 0.3 mm for containing a blood sample of 0.212  $\mu\text{L}$ .

Fig. 7 schematically illustrates an apparatus with a disposable cartridge holding a lysing reagent according to the present invention, a docking station, and a reader. In the following the operation of the apparatus for counting different types of white blood cells, namely monocytes, lymphocytes, granulocytes, and thrombocytes and for determining haemoglobin content is explained.

The lysing reagent for selectively lysing red blood cells is added to the diluent in the storage chamber 1. When the whole blood 8 is added to the opening 58 of the first capillary section 15, the blood will be dragged in to the capillary and through the middle section 10 and last section 14 of the capillary. The last section of the capillary

is connected to a fill-chamber 43 for visually verification of the filling. The fill-chamber 43 is connected through a conduct 44 to open air.

The blood filled middle section of the capillary is part of a knob 2 that can be moved to a second position, connecting the ends of the capillary to two other conducts, a  
5 conduct 45 connected to the storage chamber 1 and a second conduct 40 connected to the first mixing chamber 3 respectively. A third conduct 39 is leading from the first mixing chamber to a port opening 42 in the cartridge. The port opening is connected through a counter port opening 37 in the apparatus, through tubing 46 to a three-position valve 51 and directed through the two positions of the valve to open air  
10 through second tubing 55 or through a third tubing 50 to the suction port of a membrane pump 47.

When the blood and diluent with reagent has been sucked into the first mixing chamber, the blood can be mixed by blowing bubbles through the orifice of the sensor 4. The air pressure is applied through the collection chamber 5, via a fourth  
15 conduct 12A, a small volume chamber 6A, a fifth conduct 12B, a large volume chamber 6B and a sixth conduct 7 directed to an opening port 41 in the cartridge. A counter port 36 in the apparatus is connected through a fourth tubing 48 to a second three position valve 52, which has positions to direct to both vacuum through a fifth tubing 56 to the suction port of the membrane pump, or to the exhaust of the  
20 membrane pump, through a third two position valve 53 and a sixth tubing 49, the third valve having two positions for the connection and for directing the pump exhaust to open air through a seventh tubing 54 respectively.

After mixing the diluted and lysed blood (red blood cells is removed) it is ready to be measured. The first mixing chamber is connected through the first valve to open air  
25 and the collection chamber is connected through the second valve to the suction port of the pump. The exhaust of the membrane pump is connected through the third valve to open air. As the blood and diluent flows from the mixing chamber into the collection chamber, an electrical connection between to counter electrodes 34 and 35 placed in each chamber is established through the liquid. Cells are counted and  
30 differentiated by size according to the Coulter principle. Through sizing of the cells, the cells can be distinguished and categorised into different groups containing cells of a certain type. Thus, leucocytes can be differentiated into granulocytes, lymphocytes and monocytes. Furthermore, thrombocytes (platelets) can be differentiated from leucocytes as well. In order to determine the concentration, the volume of the diluted

blood, which has been counted, must be known. Since thrombocytes are approximately ten times as frequent as leucocytes, it may be necessary to measure two different volumes. The thrombocytes are counted according to a small volume chamber 6A positioned between the collection chamber and the larger volume. By  
5 registering the liquid entry and exit at the inlet and outlet of the small volume chamber respectively, the counting period will be given. Registration of the liquid level is preferably done by an optical reflectance measurement at the inlet 33 and at the outlet 32. The outlet of the small volume chamber is also the inlet of the large volume chamber 6B. This chamber is used in connection with counting of leucocytes. At the  
10 outlet of the large volume chamber, a third optical reflectance measurement 31 is performed to register the exit of the liquid from this chamber.

After counting both leucocytes and thrombocytes the haemoglobin content can be measured by optical spectroscopy preferably through the middle section of the large volume chamber 30.

15 The process of making a test by means of the present invention can be characterized as:

- 1) Draw blood by using a lancet device
- 2) Pick up blood droplet by touching the blood to the cartridge inlet
- 3) Mount cartridge in the instrument (instrument starts and runs the test)
- 20 4) Read the result from the display
- 5) Remove and discard cartridge

Fig. 8 shows schematically another preferred embodiment of the cartridge according to the invention. The illustrated cartridge has a first member 104 for sampling blood. The member 104 is movably positioned in relation to the housing 100 between three  
25 positions, a first position for blood sampling, a second position to connect the first storage chamber 103 with the first mixing chamber 112, and a third position to connect the second storage chamber 105 with the second mixing chamber 110. The blood is passed through the bore 122 into the first cavity of the member 104 by capillary forces or by applying a vacuum at the end of the sampling channel 111. A  
30 liquid blocking valve 116 is arranged after the first sampling member to hinder passage of blood through the channel. After the blood sampling, the sampling member is turned to the second position and the sample is flushed into the first mixing chamber 112 by the liquid in the first storage chamber 103. In the first mixing

chamber 112 the sample is diluted 1:200 with the liquid in the first storage chamber 103 and a fraction is blown back into the first cavity of the sampling member 104, which is turned to the third position so that the diluted sample is flushed into the second mixing chamber 110 by the liquid in the second storage chamber 105. In the  
5 second mixing chamber 110 the sample is further diluted 1:200 to a total dilution of 1:40.000 with the liquid in the second storage chamber 105. A hemolysing reagent is injected into the first mixing chamber 112 by a piston 115, which breaks a seal 118 between a reagent chamber 119 and the first mixing chamber 112. After hemolysing the blood the 1:200 diluted sample is ready for counting non-hemolysed white blood  
10 cells and for measuring haemoglobin by photometry. The white cells are counted by passing them through a first orifice 113 and measuring the response by impedance cell counting over a first electrode pair 117, 120. A fixed volume is counted by a first volume metering arrangement 107 connected to the first collection chamber 114. A first overflow volume 106 is arranged after the first volume metering arrangement  
15 107. The white blood cells can be differentiated by volume after adding the lysing reagent to the blood. The white cells can be grouped by volume into: Granulocytes, Monocytes and Lymphocytes. The three groups together yield the total white cell count.

In the second mixing chamber 110, red cells and platelets are counted. The red cells  
20 and platelets are counted by passing them through a second orifice 109 and measuring the response by impedance cell counting over a second electrode pair 106, 121. A fixed volume is counted by a second volume metering arrangement 101 connected to the second collection chamber 108. A second overflow volume 102 is placed after the second volume metering arrangement 101.

25 The embodiment may further comprise an additional optical detector for photometric determination of the haemoglobin content. Referred to simply as "total haemoglobin", this test involves lysing the erythrocytes, thus producing an evenly distributed solution of haemoglobin in the sample. The haemoglobin is chemically converted to the more stable and easily measured methemoglobintriazole-complex, which is a coloured  
30 compound that can be measured colorimetrically, its concentration being calculated from its amount of light absorption using Beer's Law. The method requires measurement of haemoglobin at approx. 540 nm where the absorption is high with a turbidity correction measurement at 880 nm where the absorption is low.

Fig. 9 shows schematically another preferred embodiment of the cartridge according to the invention. The illustrated cartridge has a first member 104 for sampling blood. The member 104 is movably positioned in relation to the housing 100 between two positions, a first position for blood sampling, and a second position to connect the first storage chamber 103 with the first mixing chamber 112. A blood sample is passed through the bore 122 into the first cavity of the member 104 by capillary forces or by applying a vacuum at the end of the sampling channel 111. A liquid blocking valve 116 is arranged after the first sampling member to hinder passage of blood through the channel. After the blood sampling, the sampling member is turned to the second position and the sample is flushed into the first mixing chamber 112 by the liquid in the first storage chamber 103. In the first mixing chamber 112 the sample is diluted 1:200 with the liquid in the first storage chamber 103.

The cartridge further comprises a second sampling member 124 positioned in the housing 100 for sampling a small and precise volume of liquid from the first mixing chamber 112 and having a second cavity 123 for receiving and holding the sampled liquid, the member 124 being movably positioned in relation to the housing 100 in such a way that, in a first position, the second cavity 123 is in communication with the first mixing chamber 112 for entrance of a diluted sample from the first mixing chamber 112 into the first cavity 123, and, in a second position, the second cavity 123 is in communication with the second mixing chamber 110 so that the diluted sample is flushed into the second mixing chamber 110 by the liquid in the second storage chamber 105. In the second mixing chamber 110 the sample is further diluted 1:200 to a total dilution of 1:40.000 with the liquid in the second storage chamber 105. A hemolysing reagent is injected into the first mixing chamber 112 by a piston 115, which breaks a seal 118 between a reagent chamber 119 and the first mixing chamber 112. After hemolysing the blood the 1:200 diluted sample is ready for counting non-hemolysed white blood cells and for measuring haemoglobin by photometry. The white cells are counted by passing them through a first orifice 113 and measuring the response by impedance cell counting over a first electrode pair 117, 120. A fixed volume is counted by a first volume metering arrangement 107 connected to the first collection chamber 114. A first overflow volume 106 is arranged after the first volume metering arrangement 107. The white blood cells can be differentiated by volume after adding the lysing reagent to the blood. The white cells can be grouped by volume into: Granulocytes, Monocytes and Lymphocytes. The three groups together yield the total white cell count.

In the second mixing chamber 110, red cells and platelets are counted. The red cells and platelets are counted by passing them through a second orifice 109 and measuring the response by impedance cell counting over a second electrode pair 106, 121. A fixed volume is counted by a second volume metering arrangement 101  
5 connected to the second collection chamber 108. A second overflow volume 102 is placed after the second volume metering arrangement 101.

The embodiment may further comprise an additional optical detector for photometric determination of the haemoglobin content. Referred to simply as "total haemoglobin", this test involves lysing the erythrocytes, thus producing an evenly distributed solution  
10 of haemoglobin in the sample. The haemoglobin is chemically converted to the more stable and easily measured methemoglobin triazole-complex, which is a coloured compound that can be measured colorimetrically, its concentration being calculated from its amount of light absorption using Beer's Law. The method requires measurement of haemoglobin at approx. 540 nm where the absorption is high with a  
15 turbidity correction measurement at 880 nm where the absorption is low.

## CLAIMS

1. A lysing reagent for use in a blood cell counter for counting and discriminating a plurality of cell types in one counting operation, with a lysing capability sufficient for lysing of erythrocytes while maintaining counting ability of other cell types.
- 5 2. A lysing reagent mixture according to claim 1, wherein the lysing reagent contains a surfactant.
3. A lysing reagent mixture according to claim 1 or 2, wherein the surfactant comprises a saponin.
4. A lysing reagent according to claim 1, wherein the lysing reagent comprises a  
10 quaternary ammonium salt.
5. A lysing reagent according to any of claims 1-4, wherein the other cell types can be counted and discriminated in a Coulter counter.
6. A lysing reagent according to any of claims 1-5, wherein cells of the other cell  
15 types are reduced in size and the concentration is determined by counting a representative fraction of the respective cells.
7. A lysing reagent according to any of claims 1-6, wherein the other cell types include sub-populations of leukocytes, such as lymphocytes, monocytes and granulocytes, which are selectively reduced in size by the lysing reagent and can be counted in a cell counter.
- 20 8. An automatic electronic cell counter for counting and discriminating a plurality of blood cell types in one counting operation, having a chamber holding a lysing reagent according to any of the preceding claims.
9. A cartridge for characterizing blood cells in a blood sample, comprising a housing with  
25 a first liquid storage chamber for holding a lysing reagent according to any of claims 1-7,  
a first mixing chamber and a first collection chamber separated by a wall containing a first orifice for the passage of the cells between the first mixing chamber and the first collection chamber,
- 30 first cell characterization means for characterizing cells passing through the first orifice,



a bore in the outer surface of the housing for entrance of the blood sample, communicating with

a first sampling member positioned in the housing for sampling the blood sample and having a first cavity for receiving and holding the blood sample, the member being  
5 movably positioned in relation to the housing in such a way that, in a first position, the first cavity is in communication with the bore for entrance of the blood sample into the first cavity, and, in a second position, the first liquid storage chamber communicates through the first cavity with the first mixing chamber so that the blood sample can be flushed with discharged liquid from the first liquid storage chamber into the first  
10 mixing chamber.

10. A cartridge according to claim 9, further comprising

a second mixing chamber and a second collection chamber separated by a second wall containing a second orifice for the passage of the cells between the second mixing chamber and the second collection chamber,

15 second cell characterization means for characterizing cells passing through the second orifice, and wherein

in the second position, the first cavity is in communication with the first mixing chamber for entrance of liquid from the first mixing chamber into the first cavity, and, in a third position, the first cavity is in communication with the second mixing chamber  
20 for discharge of the liquid in the first cavity into the second mixing chamber.

11. A cartridge according to claim 9, further comprising

a second mixing chamber and a second collection chamber separated by a second wall containing a second orifice for the passage of the cells between the second mixing chamber and the second collection chamber,

25 second cell characterization means for characterizing cells passing through the second orifice, and

a second sampling member positioned in the housing for sampling a small and precise volume of liquid from the first mixing chamber and having a second cavity for receiving and holding the sampled liquid, the member being movably positioned in  
30 relation to the housing in such a way that, in a first position, the second cavity is in communication with the first mixing chamber for entrance of liquid from the first mixing chamber into the first cavity, and, in a second position, the second cavity is in

communication with the second mixing chamber for discharge of the sampled liquid in the second cavity into the second mixing chamber.

12. A cartridge according to any of claims 9-11, further comprising a reagent chamber positioned adjacent to the first mixing chamber for holding a reagent to be entered  
5 into the first mixing chamber.

13. A cartridge according to claim 12, further comprising a breakable seal separating the reagent chamber from the first mixing chamber.

14. A cartridge according to any of claims 9-13, wherein a mixing member is positioned in at least one of the mixing chambers.

10 15. A cartridge according to any of claims 9-14, further comprising a sensor for characterization of the liquid.

16. A cartridge according to claim 15, wherein the sensor for characterization of the liquid is adapted for spectrophotometric characterization of the liquid.

15 17. A cartridge according to any of claims 9-16, wherein the orifice has a diameter in the range from 30  $\mu\text{m}$  to 100  $\mu\text{m}$ .


18. A cartridge according to claim 17, wherein the orifice has a diameter in the range from 35  $\mu\text{m}$  to 50  $\mu\text{m}$ .

19. A cartridge according to claim 17, wherein the orifice has a diameter in the range from 30  $\mu\text{m}$  to 45  $\mu\text{m}$ .

20 20. A cartridge according to claim 17, wherein the orifice has a diameter in the range from 35  $\mu\text{m}$  to 40  $\mu\text{m}$ .


21. A cartridge according to claim 17, wherein the orifice has a diameter substantially equal to 40  $\mu\text{m}$ .

1/9



**Fig. 1**

2/9



WBC = Leukocytes

LYM = Lymphocytes


GRN = Granulocytes

MON = Monocytes


PLT = Thrombocytes

**Fig. 2**

**3/9**




**Fig. 3**




**Fig. 4**


4/9

**Fig. 5**

5/9

**Fig. 6**


6/9




47 Fig. 7




7/9

**Fig. 8**

8/9

**Fig. 9**

9/9



**Fig. 10**

## INTERNATIONAL SEARCH REPORT

PCT/EP 03/00383

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 G01N15/12 G01N33/80

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 731 206 A (FISCHER TIMOTHY J ET AL) 24 March 1998 (1998-03-24)	1-8
Y	claim 1 column 10, line 20 - line 58 ---	9-21
X	US 5 316 951 A (CARVER DIANE D ET AL) 31 May 1994 (1994-05-31)	1-8
Y	abstract column 1, line 10 - line 25 column 4, line 6 - line 40 ---	9-21
A	WO 01 11338 A (LARSEN ULRIC DARLING) 15 February 2001 (2001-02-15)	1-8
Y	abstract; figure 1 page 7, line 1 - line 23 page 21, line 9 - line 14 page 24, line 4 - line 15 ---	9-21
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
"&" document member of the same patent family

Date of the actual completion of the international search

7 October 2003

Date of mailing of the international search report

23. 10. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

MALIN SÖDERMAN /EÖ

## INTERNATIONAL SEARCH REPORT

PCT/03/00383

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 319 209 B1 (KRIZ DARIO) 20 November 2001 (2001-11-20)	1-8
Y	abstract column 1, line 52 - line 55 column 2, line 38 - line 45; figures 1-4 column 5, line 40 - line 49 ---	9-21
P,Y	WO 02 089670 A (CHEMPAQ APS ;LARSEN ULRIK DARLING (DK)) 14 November 2002 (2002-11-14)	9-21
P,A	abstract; figures 1-3 ---	1-8
A	US 5 501 982 A (RUTNARAK SANGVORN ET AL) 26 March 1996 (1996-03-26) abstract column 1-2 ---	1-21
A	US 4 521 729 A (ROGGENKAMP HANS-GUNTHER ET AL) 4 June 1985 (1985-06-04) abstract; figures 1,2 column 4, line 27 - line 45 column 9, line 38 - line 47 ---	1-21
A	US 3 122 431 A (COULTER WALLACE H ET AL) 25 February 1964 (1964-02-25) column 2, line 54 - line 55 ---	17-21
A	EP 1 182 457 A (MALLINCKRODT BAKER B V) 27 February 2002 (2002-02-27) page 7, line 18 - line 25 ---	17-21
Y	US 3 549 994 A (ROTHERMEL WILLIAM F ET AL) 22 December 1970 (1970-12-22)	9-21
A	column 1, line 15 - line 36 -----	1-8

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 03/00383

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-21  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/DK 03/00383

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-21

Present claims 1-21 relate to a compound defined by reference to a desirable characteristic or property, namely a lysing capability sufficient for lysing erythrocytes while maintaining counting ability of other cells. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lacks clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the cartridge, described in claims 9-21 and in the description at page 3, lines 4-14, page 5, line 1-page 9, line 4, page 9, line 19-page 10, line 22, page 13, line 14-page 21, line 15.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/03/00383

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5731206	A	24-03-1998	AU 1541788 A	10-10-1988
			CA 1338603 C	24-09-1996
			CN 1030481 A ,B	18-01-1989
			DE 3854983 D1	21-03-1996
			DE 3854983 T2	26-09-1996
			DE 3855919 D1	26-06-1997
			DE 3855919 T2	16-10-1997
			DE 305491 T1	16-11-1989
			EP 0305491 A1	08-03-1989
			EP 0627624 A1	07-12-1994
			ES 2010248 A6	01-11-1989
			IL 85532 A	29-03-1992
			JP 1502931 T	05-10-1989
			JP 2796325 B2	10-09-1998
			WO 8807187 A1	22-09-1988
			US 5155044 A	13-10-1992
US 5316951	A	31-05-1994	US 5316725 A	31-05-1994
			WO 9532622 A1	07-12-1995
			EP 0762828 A1	19-03-1997
WO 0111338	A	15-02-2001	AU 6280000 A	05-03-2001
			CA 2381285 A1	15-02-2001
			WO 0111338 A1	15-02-2001
			EP 1206692 A1	22-05-2002
US 6319209	B1	20-11-2001	AU 7034000 A	19-03-2001
			CA 2380657 A1	01-03-2001
			EP 1206217 A1	22-05-2002
			WO 0113795 A1	01-03-2001
			JP 2003507719 T	25-02-2003
			NO 20020733 A	13-02-2002
WO 02089670	A	14-11-2002	WO 02089670 A1	14-11-2002
US 5501982	A	26-03-1996	AU 1258495 A	10-07-1995
			WO 9517658 A1	29-06-1995
US 4521729	A	04-06-1985	DE 3215719 A1	03-11-1983
			AT 24054 T	15-12-1986
			DE 3368127 D1	15-01-1987
			DK 186583 A	29-10-1983
			EP 0092775 A1	02-11-1983
			ES 8402424 A1	16-04-1984
			FI 831414 A	29-10-1983
			JP 59015849 A	26-01-1984
			NO 831488 A	31-10-1983
			PT 76613 A ,B	01-05-1983
US 3122431	A	25-02-1964	US 2985830 A	23-05-1961
			FR 1238032 A	05-08-1960
			GB 907028 A	26-09-1962
			NL 127771 C	
			NL 240601 A	
			NL 6902746 A	27-05-1969
EP 1182457	A	27-02-2002	EP 1182457 A1	27-02-2002
			AU 9243901 A	25-02-2002



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP03/00383

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 1182457	A		EP	1309862 A1	14-05-2003
			WO	0214861 A1	21-02-2002
-----					
US 3549994	A	22-12-1970	FR	1496169 A	29-09-1967
			AT	269390 B	10-03-1969
			AU	4759672 A	15-08-1974
			BE	701846 A	02-01-1968
			BE	713776 A	17-10-1968
			CA	936018 A1	30-10-1973
			CA	931508 A1	07-08-1973
			CH	494963 A	15-08-1970
			CH	563184 A5	30-06-1975
			CH	509588 A	30-06-1971
			CH	517295 A	31-12-1971
			CH	518730 A	15-02-1972
			CH	501924 A	15-01-1971
			DE	1773226 A1	27-04-1972
			DE	1798430 A1	04-01-1973
			DE	1798431 A1	15-02-1973
			DE	1798432 A1	04-01-1973
			DE	2009713 A1	17-09-1970
			DE	2249554 A1	26-04-1973
			DE	1300208 B	31-07-1969
			DK	141079 B	07-01-1980
			ES	352852 A1	16-01-1970
			ES	367188 A1	01-01-1972
			ES	367189 A1	01-04-1971
			ES	367190 A1	01-04-1971
			ES	407499 A1	16-10-1975
			FR	2034613 A1	11-12-1970
			FR	2157374 A5	01-06-1973
			FR	1571423 A	20-06-1969
			GB	1305813 A	07-02-1973
			GB	1369557 A	09-10-1974
			GB	1194584 A	10-06-1970
			GB	1232701 A	19-05-1971
			GB	1232702 A	19-05-1971
			GB	1232703 A	19-05-1971
			GB	1232704 A	19-05-1971
			GB	1232705 A	19-05-1971
			IL	29836 A	29-02-1972
			IL	38219 A	28-02-1973
			IL	40531 A	15-10-1975
			IT	966272 B	11-02-1974
			JP	49000225 B	07-01-1974
			JP	54002598 B	09-02-1979
			JP	55006192 B	14-02-1980
			JP	48046773 A	03-07-1973
			LU	54155 A1	21-09-1967
			NL	6709747 A	29-01-1968
			NL	6805384 A	18-10-1968
			NL	7213663 A	25-04-1973
			SE	337706 B	16-08-1971
-----					

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**